Lung cancer remains the leading cause of cancer-related deaths worldwide. Managing cancer treatment during pregnancy is a rare yet challenging condition, with limited data available on maternal and neonatal outcomes. We present the case of a 37-year-old pregnant woman diagnosed with ROS-1-rearranged metastatic NSCLC, who was treated with crizotinib and subsequently delivered a preterm infant. Our report underscores the critical need for rigorous thromboembolic monitoring in pregnant patients undergoing cancer treatment. Furthermore, we provide evidence that placental tissue significantly reduces fetal crizotinib exposure, suggesting that crizotinib might be a viable therapeutic option for maintaining a pregnancy during lung cancer treatment.
Weber et al. (2026) studied this question.